Monday's top brokerage calls: Cipla, L&T and more

SUMMARY

JPMorgan and Goldman Sachs are 'neutral' on Cipla after its March quarter earnings while both are bullish on L&T after results. Here's a look at the top brokerage calls for today:

By CNBCTV18.comMay 17, 2021 9:01:54 AM IST (Published)

JPMorgan on Cipla: The brokerage maintains a 'neutral' call on the stock with a target at Rs 785 per share. It said that the firm reported weak earnings for the March quarter as the US margin disappointed.

Goldman Sachs on Cipla: The brokerage has a 'neutral' call on the stock with a target at Rs 890 per share. Gross margin was impacted from shelf stock adjustments in the US and inventory write-off, noted the brokerage.

Morgan Stanley on Cipla: The brokerage is 'overweight' on the stock with a target at Rs 949 per share. The company continues to strengthen its base business in India, the US and South Africa, it says.

Kotak on Escorts: The brokerage has a 'buy' call on the stock with a target at Rs 1,700 per share. It expects the tractor industry to show strong growth over the next 2 years.

JPMorgan on L&T: The brokerage is 'overweight' on the stock with a target at Rs 1,815 per share. It cut CY22/23 EPS estimates by 3 percent/4 percent.

Goldman Sachs on L&T: The brokerage maintains a 'buy' call on the stock with a target at Rs 2,000 per share. It believes "stars are aligning for the next leg of capex uptick in India".

Nomura on L&T: The brokerage has a 'buy' call on the stock with a target at Rs 1,654 per share. The brokerage expects a strong order book and higher services driving growth into FY23.

Morgan Stanley on Dr Reddy's: The brokerage is 'overweight' on the stock with a target at Rs 5,859 per share. Kuvan, Vascepa, Revlimid generic & Sputnik are near-to-mid-term growth drivers, it said.

JPMorgan on Dr Reddy's: The brokerage has a 'neutral' call on the stock with a target at Rs 4,850 per share. It believes the best for the stock is behind us.

Goldman Sachs on Dr Reddy's: The brokerage has a 'neutral' call on the stock with a target at Rs 5,250 per share. The intensity of the US market pricing pressure and US FDA GMP compliance are the key risks, it said.